Endogenous analgesia mediated by CD4 T lymphocytes is dependent on enkephalins in mice by unknown
RESEARCH Open Access
Endogenous analgesia mediated by CD4+ T
lymphocytes is dependent on enkephalins
in mice
Lilian Basso1†, Jérôme Boué1†, Karim Mahiddine2, Catherine Blanpied1, Sébastien Robiou-du-Pont1,
Nathalie Vergnolle1, Céline Deraison1 and Gilles Dietrich1*
Abstract
Background: T cell-derived opioids play a key role in the control of inflammatory pain. However, the nature of
opioids produced by T cells is still matter of debate in mice. Whereas β-endorphin has been found in T
lymphocytes by using antibody-based methods, messenger RNA (mRNA) quantification shows mainly mRNA
encoding for enkephalins. The objective of the study is to elucidate the nature of T cell-derived opioids responsible
for analgesia and clarify discrepancy of the results at the protein and genetic levels.
Methods: CD4+ T lymphocytes were isolated from wild-type and enkephalin-deficient mice. mRNA encoding for
β-endorphin and enkephalin was quantified by RT-qPCR. The binding of commercially available polyclonal
anti-endorphin antibodies to lymphocytes from wild-type or enkephalin knockout mice was assessed by
cytofluorometry. Opioid-mediated analgesic properties of T lymphocytes from wild-type and enkephalin-deficient
mice were compared in a model of inflammation-induced somatic pain by measuring sensitivity to mechanical
stimuli using calibrated von Frey filaments.
Results: CD4+ T lymphocytes expressed high level of mRNA encoding for enkephalins but not for β-endorphin in
mice. Anti-β-endorphin polyclonal IgG antibodies are specific for β-endorphin but cross-react with enkephalins.
Anti-β-endorphin polyclonal antibodies bound to wild-type but not enkephalin-deficient CD4+ T lymphocytes.
Endogenous regulation of inflammatory pain by wild-type T lymphocytes was completely abolished when T
lymphocytes were deficient in enkephalins. Pain behavior of immune-deficient (i.e., without B and T lymphocytes)
mice was superimposable to that of mice transferred with enkephalin-deficient lymphocytes.
Conclusions: Rabbit polyclonal anti-β-endorphin serum IgG bind to CD4+ T lymphocytes because of their
cross-reactivity towards enkephalins. Thus, staining of T lymphocytes by anti-β-endorphin polyclonal IgG reported in
most of studies in mice is because of their binding to enkephalins. In mice, CD4+ T lymphocytes completely lose
their analgesic opioid-mediated activity when lacking enkephalins.
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Background
In inflammatory conditions, pain is regulated by endogen-
ous opioids produced by immune cells. Inflammation-
induced somatic pain is first attenuated by opioid-
producing inflammatory cells including neutrophils and
macrophages, and then, few days later, abolished by
opioid-producing T lymphocytes entering the site of in-
flammation [1–5]. Although all three μ, δ, and k sub-
classes of opioid receptors are expressed in peripheral
endings of afferent neurons, only the δ-type opioid recep-
tor (DOR) is involved in the spontaneous regulation of
somatic complete Freund’s adjuvant (CFA)-induced in-
flammatory pain in mice [6–9]. In line with the pivotal
role of DOR in the endogenous regulation of inflamma-
tory somatic pain in mice, we reported that effector T
lymphocytes produce enkephalins, the most selective en-
dogenous ligands for DOR, but virtually not β-endorphin
[1, 6, 10]. Although enkephalins are commonly described
in mouse T lymphocytes, numerous laboratories also
found β-endorphin. All the studies reporting β-endorphin
in mouse T lymphocytes were performed by using im-
munochemistry methods with rabbit anti-β-endorphin
polyclonal IgG antibodies [11–16]. The specificity of anti-
β-endorphin IgG antibodies towards β-endorphin was
clearly demonstrated by the absence of cross-species bind-
ing of the Ig heavy chain constant region to the Fc recep-
tors expressed on leukocytes (staining with isotype-
matched control antibodies) together with the complete
inhibition of the anti-β-endorphin IgG binding by β-
endorphin. However, these experiments that showed the
specificity of polyclonal anti-β-endorphin IgG towards the
multiple epitopes of β-endorphin polypeptide, did not ex-
clude that they could cross-react (i.e., to recognize the
same epitope on two distinct antigens) with Met-
enkephalin, a five-amino-acid peptide corresponding to
one epitope of the β-endorphin (Fig. 1). Given that mes-
senger RNA (mRNA) expression analysis showed that acti-
vated mouse T lymphocytes expressed mRNA encoding for
proenkephalin (PENK) but not for proopiomelanocortin
(POMC) [1, 6, 10], we assumed that the binding of anti-β-
endorphin IgG antibodies to T lymphocytes was due to the
recognition of Met-enkephalin.
Here, we show that the intracytoplasmic staining of acti-
vated mouse T lymphocytes by anti-β-endorphin poly-
clonal IgG is due to cross-reactivity towards enkephalin.
Moreover, we show that the endogenous regulation of
inflammatory somatic pain by CD4+ T lymphocytes in




C57BL/6 mice were provided from Janvier (Le Genest
Saint Isle, France) and recombination-activating gene 2-
deficient C57BL/6 (RAG2−/−) mice were from ANEXPLO
platforms (UMS 006, Toulouse, France). Pre-
proenkephalin knockout (PENK−/−) mice were the
B6.129-Penk-rstm1Pig/J strain with a genetic background
C57BL/6 (MHC H-2 Haplotype b) provided by The Jack-
son Laboratory (Bar Harbor, Maine, USA). All mice used
in the study were 8–10-week-old male weighing 20–25 g.
Mice were housed at a temperature between 20 and 22 °C
and maintained under a 12-h light/dark cycle in sawdust
coated transparent cages. Animals were housed by three
or two in ventilated cages with chow and water ad libitum.
All experiments involving animals were performed in
accord with ethical guidelines (INSERM) and were
approved by the Midi-Pyrénées (France) ethics committee
(application Number MP/06/73/10/12).
Isolation and activation of CD4+ T lymphocytes
CD4+ T lymphocytes were isolated from splenocytes
using cell negative isolation kits according to the manu-
facturer’s instructions (Invitrogen Dynal AS, Oslo,
Norway). Twenty-four-well cell culture plates (Corning,
Life Sciences, Amsterdam, Netherlands) previously
coated with 2.5 μg mL−1 of anti-CD3 (clone 145-2C11)
and 2.5 μg mL−1 of anti-CD28 (clone 37.51) monoclonal
Fig. 1 Schematic representation of the potential cross-reactivity of anti-Met-enkephalin and anti-β-endorphin polyclonal IgG antibodies. The
amino acid sequence of Met-enkephalin (five amino acids corresponding to only one epitope, gray box) is identical to the first five amino acids of
the β-endorphin and may be recognized by immune serum IgG specifically raised against Met-enkephalin ( ) or β-endorphin ( )
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antibodies (mAbs) (BD Biosciences, San Jose, CA) were
seeded with 5 × 105 purified naive CD4+ T cells (more
than 92 % pure) in RPMI-1640 medium (GIBCO Life
Technologies, Paisley, UK) supplemented with 10 % heat
inactivated fetal calf serum (GIBCO Life Technologies),
1 % non-essential amino acids, 4-mM L-glutamine, 1-
mM sodium pyruvate, 100-IU/ml penicillin, 100-μg/ml
streptomycin (GIBCO-BRL), 10-mM HEPES (4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid), and 2 ×
10-5 M 2-β-Mercapto-ethanol.
Cytofluorometric analysis of antibody activity
106 cells were incubated with anti-CD16/CD32 (mouse
Fc block™, clone 2.4G2, BD Biosciences), fixed and
permeabilized with BD Cytofix/Cytoperm solution be-
fore being incubated with 100 μL of either rabbit anti-β-
endorphin polyclonal IgG (10 μg mL−1, Merck-Millipore
(Chemicon International), Temecula, CA), rabbit anti-
Met-enkephalin polyclonal IgG (10 μg mL−1, Merck-
Millipore (Chemicon International), Temecula, CA), or
rabbit non-immune serum IgG (10 μg mL−1, Jackson
Immunoresearch Lab) diluted in PBS containing 1 %
fetal calf serum and 2 mM EDTA. After washing, cell-
bound antibodies were revealed using fluorescein iso-
thiocyanate (FITC)-conjugated goat anti-rabbit IgG sec-
ondary antibodies (BD Biosciences). Data were collected
on 20,000 cells by forward and side scatter intensity on
an FACs calibur flow cytometer (Becton Dickinson,
Franklin Lakes, NJ) and were subsequently analyzed
using the Flow Jo software (Tree Star Inc., Ashland,
OR). The neuroepithelioma cell line SK-N-MC was
grown in DMEM supplemented with 10 % fetal-calf
serum at 37 °C with 5 % CO2 in air atmosphere until the
cells reach 80 % confluence [17].
For inhibition experiments, rabbit anti-β-endorphin or
anti-Met-enkephalin antibodies were incubated with 10 μM
of soluble β-endorphin (Sigma-Aldrich, St. Louis, MO) or
Met-enkephalin (Sigma-Aldrich, St. Louis, MO) for 20 min
at 37 °C before being added to the cells overnight at 4 °C
[18]. After washing, cell-bound antibodies were revealed
using fluorescein isothiocyanate (FITC)-conjugated goat
anti-rabbit IgG secondary antibodies as described above.
Real-time PCR analysis
Total RNA was isolated by TRIzol™ Reagent and reverse-
transcribed with Moloney murine leukemia virus reverse
transcriptase using random hexamers for priming. Tran-
scripts encoding hypoxanthine phosphoribosyl transferase
(HPRT), proenkephalin (PENK), and proopiomelanocortin
(POMC) were quantified by real-time PCR in mouse CD4+
T cells. Forward and reverse primers were 5′-GTTCT
TTGCTGACCTGCTGGAT-3′ and 5′-CCCCGTTGACT-
GATCATTACAG-3′ for HPRT, 5′-CGACATCAATTT
CCTGGCGT-3′ and 5′-AGATCCTTGCAGGTCTCCCA-
3′ for PENK, and 5′-TGGCCCTCCTGCTTCAGAC-3′
and 5′-CAGCGAGAGGTCGAGTTTGC-3′ for POMC,
[19]. The target gene expression was normalized to the
HPRT mRNA and quantified relative to a standard comple-
mentary DNA (cDNA) (calibrator sample) prepared from
mouse brain using the 2−ΔΔCT method, where ΔΔCT =ΔCT
sample −ΔCT calibrator [20].
Spleen cell transfer, immunization, and measurement of
somatic nociception in mice
Splenocytes (30 × 106) isolated from either wild-type
C57BL/6 (PENK+/+) or pre-proenkephalin knockout
(PENK−/−) mice were intravenously (i.v.) injected into
immunodeficient RAG2
−/− mice. Mice were housed by
three or two in ventilated cages. The next day, recipient
mice were immunized by injecting subcutaneously (s.c.)
into hind footpads ovalbumin (OVA, Sigma Chemical
Co., St Louis, MO) emulsified in complete Freund’s ad-
juvant (CFA) (50 μl at 1 mg mL−1).
Mechanical withdrawal thresholds were measured
using ascending series calibrated von Frey filaments of
binding forces ranging from 0.04 to 2 g (Stoelting, Wood
Dale, IL, USA), applied onto the plantar surface of mice.
Threshold to mechanical stimuli was calculated as the
force value of the von Frey filament triggering three paw
withdrawals over five applications. Responses to mech-
anical stimuli were recorded before, and daily after
immunization. The groups of mice treated with nalox-
one methiodide (NLX) were injected (10 μl at 2 mg mL
−1) into the ankle of the inflamed hind paw, 30 min be-
fore each pain assessment [1]. Naloxone methiodide
treatment was initiated on day 3 after immunization
when T cells become the predominant immune cells at
the inflammatory site [2].
Statistical analysis
Data are expressed as mean± SEM. Due to the skewed
distribution of the responses, non-parametric tests were
applied on longitudinal data using a ranked-based ap-
proach on factorial experiments [21, 22]. Statistics tests
were computed using modified ANOVAs with the R
software package “nparLD” for longitudinal data [23].
Mann-Whitney-Wilcoxon tests were used for the post
hoc analysis using R 3.0.2. p < 0.05 was considered as
significant.
The statistical model assessed response over time be-
tween treatment groups including an interaction term be-
tween treatment groups and days of measurement as fixed
effects and a random effect to account for the mice re-
peated measures over time. The variable treatment was
considered as factorial experiment. We first tested
whether response over time differed across the five treat-
ment groups (RAG2−/−, PENK+/+, PENK+/+ NLX, PENK−/−
and PENK−/− NLX). Significant (p < 0.05) differences of
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response between groups allowed performing subsequent
analysis of a random effect to account for the mice
repeated measures over time. All pairwise combinations of
treatment were tested to assess their effect on response. Fi-
nally, we also compared response between treatments at
each time point using a Mann-Whitney-Wilcoxon test.
Results
Anti-β-endorphin polyclonal IgG antibodies cross-react
with enkephalins expressed in activated T lymphocytes
Purified naive wild-type CD4+ T lymphocytes were stim-
ulated with a cocktail of anti-CD3 and anti-CD28 anti-
bodies for 6 days in vitro. Expression of mRNA
encoding for PENK and POMC was then quantified by
real-time PCR. As shown in Fig. 2, mRNA encoding
PENK was upregulated upon activation of CD4+ T lym-
phocytes. By contrast, mRNA encoding POMC remained
undetectable on day 6 of activation (Fig. 2, lower panel).
The upregulation of PENK mRNA was correlated with
an intracytoplasmic accumulation of Met-enkephalin-
containing peptides as assessed by cytofluorometry
(Fig. 2, upper panel).
Contrasting with our results at the genetic level, a
number of studies found β-endorphin in mouse T lym-
phocytes by using anti-β-endorphin polyclonal serum
IgG. Given that Met-enkephalin matches to the NH2
terminal segment of the β-endorphin sequence, we
assessed the ability of anti-β-endorphin polyclonal IgG
to cross-react with Met-enkephalin (Fig. 1). As shown in
Fig. 3, polyclonal rabbit IgG directed against β-
endorphin as well as those directed against Met-
enkephalin bound to activated T lymphocytes, while
control rabbit non-immune serum IgG did not. The
binding of anti-β-endorphin and anti-enkephalin IgG to
T lymphocytes was wholly inhibited when they were
pre-incubated with either soluble β-endorphin or Met-
enkephalin (Fig. 3, middle and right panels) indicating
that anti-β-endorphin and anti-enkephalin IgG recognize
both β-endorphin and enkephalin. The complete inhib-
ition by soluble Met-enkephalin of the binding of anti-β-
endorphin IgG to T lymphocytes (Fig. 3, right panel)
demonstrates that anti-β-endorphin polyclonal IgG
recognize Met-enkephalin but not β-endorphin in T
lymphocytes.
By contrast, the binding of polyclonal anti-β-
endorphin IgG to SK-N-MC cells, which express low
levels of POMC mRNA (data not shown), was totally
inhibited by β-endorphin (Fig. 4c) and partially by Met-
enkephalin (Fig. 4d), demonstrating that the pre-
absorption of anti-β-endorphin IgG antibodies with
Met-enkephalin does not neutralize the binding to the
other epitopes of the β-endorphin (Fig. 4d).
Fig. 2 Proenkephalin is upregulated upon T cell activation. Naive CD4+ T lymphocytes isolated from wild-type mice were stimulated with both
anti-CD3 and anti-CD28 mAbs for 6 days. Expression levels of mRNA encoding for PENK (gray histogram) and POMC (white histogram) were
quantified by real-time PCR in CD4+ T lymphocytes from day 1 to day 6 (lower panels). mRNA content was normalized to the HPRT mRNA
and quantified relative to standard mouse brain cDNA. Gene expression was assessed in at least five independent experiments run in duplicate.
Results (mean ± SEM) are expressed relative to PENK or POMC mRNA expression in the mouse brain. Intracytoplasmic accumulation of
Met-enkephalin-containing peptides was then assessed by cytofluorometry (upper panels). CD4+ T lymphocytes recovered each day of the
stimulation were incubated with either control rabbit IgG (white histogram) or rabbit anti-Met-enkephalin IgG antibodies (gray histogram).
The figure shows one representative experiment out of three performed
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In order to confirm that the binding of polyclonal anti-
β-endorphin antibodies to activated mouse CD4+ T lym-
phocytes was due to the recognition of Met-enkephalin,
we assessed the binding of anti-β-endorphin antibodies to
enkephalin-deficient CD4+ T lymphocytes. As shown in
Fig. 5, anti-β-endorphin antibodies bound to wild-type but
not to PENK-deficient CD4+ T lymphocytes.
Taken together, the data show that (1) activated CD4+
T lymphocytes do not express β-endorphin in mice and
(2) the binding of rabbit polyclonal anti-β-endorphin
serum IgG to activated mouse CD4+ T lymphocytes is
because of their cross-reactivity towards enkephalins.
Analgesic activity of activated CD4+ T lymphocytes is
dependent on enkephalins
The fundamental role of T cell-derived enkephalins in the
regulation of inflammatory pain was appreciated by com-
paring mechanical sensitivity of mice in which lympho-
cytes express or not enkephalins. Immune-deficient RAG2
−/− mice transferred with splenocytes originating from
either wild-type C57BL/6 (PENK+/+) or enkephalin-
deficient knockout (PENK−/−) mice were injected with
complete Freund’s adjuvant (CFA). The nociceptive
response to mechanical stimuli was then estimated by
using calibrated von Frey filaments. Basal mechanical sen-
sitivity measured in contralateral hind paw (non-injected
with CFA) was superimposable in all the groups of mice
(Fig. 6). Within 5 days following the injection of CFA,
mechanical sensitivity of the ipsilateral paw was similar in
RAG2−/− mice transferred with PENK+/+ or PENK−/− lym-
phocytes. The sensitivity to mechanical stimuli decreased
in RAG2−/− transferred with PENK-expressing T lympho-
cytes 3 days before those transferred with PENK-deficient
T lymphocytes (Fig. 6a). From day 6 to day 10, the noci-
ceptive response to mechanical stimuli was significantly
lower in mice transferred with wild-type PENK+/+ T
lymphocytes as compared to those transferred with
PENK-deficient T lymphocytes (F = 23, p < 0.00001),
(Fig. 6a). Mechanical sensitivity was similar between non-
transferred immunodeficient RAG2−/− mice that do not
Fig. 3 Anti-β-endorphin polyclonal IgG antibodies recognize enkephalins expressed in activated T lymphocytes as assessed by cytofluorometry.
CD4+ T lymphocytes isolated from wild-type C57Bl/6 PENK+/+ mice were stimulated with both anti-CD3 and anti-CD28 mAbs for 6 days and
intracellularly stained with control rabbit non-immune serum IgG (upper panels), rabbit anti-β-endorphin polyclonal IgG antibodies (middle panels),
or rabbit anti-Met-enkephalin polyclonal IgG antibodies (lower panels). The figure depicts the binding of each of the three rabbit polyclonal IgG in
the absence (i) or in the presence of an excess of soluble β-endorphin (ii) or Met-enkephalin (iii). The figure shows one representative experiment
out of four performed. Schematic interpretation of the experiments is shown on the right of each histogram
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have lymphocytes and those transferred with enkephalin-
deficient lymphocytes (Fig. 6a) (F = 0.13, p = 0.72) indicat-
ing that enkephalins are the main opioids released by T
lymphocytes within the inflammatory site at the late stage
of CFA-induced inflammation. The fundamental role of
enkephalins in T cell-mediated analgesia was confirmed
by using naloxone methiodide, an antagonist of the three
classes of opioid receptors unable to cross the blood-brain
barrier (Fig. 6b). Whereas local administration of naloxone
methiodide worsened CFA-induced inflammatory pain in
mice with enkephalin-producing T lymphocytes (F = 21, p
= 0.00001), it had no effect in mice with enkephalin-
deficient T lymphocytes (Fig. 6) (F = 0.44, p = 0.51),
(Fig. 6).
Discussion
During microbe-induced inflammation, leukocytes at the
inflammatory site produce opioids and contribute to
modulate the intensity of the inflammation-related pain
[24]. As shown in CFA-induced pain model in mice, the
contribution of leukocytes in regulating pain varies at
the different steps of the inflammatory process. At the
early stage of inflammation, neutrophils and monocytes
that first enter the site of inflammation produce opioids
but the release of their opioid content is insufficient to
spontaneously abolish painful perception [3, 19, 25].
From the third day of inflammation, effector CD4+ T
lymphocytes generated in response to bacterial antigens
contained in CFA migrate into the inflammatory site to
enhance innate immune response against microbes. Ef-
fector CD4+ T lymphocytes, which become the predom-
inant immune cell subset in the inflammatory site,
release opioids. Activation of opioid receptors expressed
on sensory neurons innervating the inflamed area by T
lymphocyte-derived opioids is, at this time, sufficiently
efficient to relieve from CFA-induced inflammatory pain
[1, 2]. The ability of CD4+ T lymphocytes to produce
opioids is acquired upon antigen priming in draining
lymph nodes [1] and correlates with the stimulatory po-
tency of antigen-presenting cells [6]. Effector CD4+ T
lymphocytes entering the inflammatory site release their
opioid content upon stimulation by the cognate antigens
in situ [6]. A 6-day latency between immunization (i.e.,
CFA injection) and analgesia (Fig. 6) is required for
antigen-specific priming, clonal expansion, and differen-
tiation of CD4+ T lymphocytes within the draining
lymph nodes and their recruitment in sufficient number
at the site of inflammation [1, 26, 27]. The kinetics of
the allodynic response to mechanical stimuli of immu-
nodeficient mice transferred with PENK+/+ T lympho-
cytes was similar to that of wild-type immunocompetent
mice [1, 8]. The production of enkephalins by effector T
lymphocytes generated in response to CFA (mycobacter-
ium tuberculosis) reduces almost by two the duration of
somatic inflammatory pain in mice [1, 8, 26]. Given the
anti-inflammatory properties of endogenous opioids
[28–31], the analgesic effects of T cell-derived enkepha-
lins in the chronic model of CFA-induced inflammation
are certainly not restricted to their inhibitory action on
sensory neurons [10].
The production of endogenous opioids by effector
CD4+ T lymphocytes in humans and rodents is com-
monly admitted, but the nature of the opioid peptides
may differ across animal species [1, 4, 32, 33]. Contrast-
ing with the experiments performed in humans and rats,
Fig. 4 The binding of anti-β-endorphin antibody to
β-endorphin-expressing SK-N-MC cells is partially inhibited
by soluble Met-enkephalin as assessed by cytofluorometry. The
human neuroblastoma cell line SK-N-MC expressing both enkephalin
and β-endorphin was intracellularly stained with control rabbit
non-immune serum IgG (a) or rabbit anti-β-endorphin polyclonal
IgG antibodies in the absence (b) or in the presence of an excess of
soluble β-endorphin (c) or Met-enkephalin (d). The figure shows
one representative experiment out of three performed. Schematic
interpretation of the experiments is shown on the right of
each histogram
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which described at both genetic and protein levels [34–
36] the expression of β-endorphin in immune cells in-
cluding T lymphocytes, the studies performed in mice
only used antibody-based methods. To our knowledge,
all the studies describing β-endorphin in mouse T
lymphocytes have been performed by immunochemistry
methods using polyclonal anti-β-endorphin antibodies
[11–16]. Accordingly, Met-enkephalin, which constitutes
the first five amino acids of the NH2 terminus of the β-
endorphin, may be recognized as an epitope by immune
serum IgG raised against β-endorphin. Polyclonal anti-β-
endorphin antibodies are specific for β-endorphin but
cross-react with Met-enkephalin, and thereby, they bind
to cells producing β-endorphin and/or Met-enkephalin.
Their binding is always fully inhibited by soluble β-
endorphin even if the cells only produce Met-enkephalin.
However, the total inhibition of the anti-β-endorphin IgG
binding by soluble Met-enkephalin indicates that the tar-
get cells only express Met-enkephalin (i.e., the anti-β-
endorphin antibody staining is due to the recognition of
Met-enkephalin). Thus, the absence of β-endorphin-
encoding mRNA (POMC) in T lymphocytes [1, 6, 10], the
full inhibition of the anti-β-endorphin antibody binding to
wild-type CD4+ T lymphocytes by Met-enkephalin, and
the inability of anti-beta-endorphin antibodies to bind to
PENK−/− lymphocytes argue for the expression of enkeph-
alins but not β-endorphin in mouse T lymphocytes.
All the three subclasses of opioid receptors are expressed
on sensory neurons innervating skin and gastrointestinal
tract [37, 38], and CD4+ T lymphocytes have been shown
to be the most effective regulators of pain upon chronic in-
flammation including intestinal inflammation in mice [1, 6,
10, 13–15]. However, although opioid drugs specific for
each of the three opioid receptors are efficient to relieve in-
flammatory pain when administered in periphery [6, 39–
41], the molecular nature of the endogenous opioids
produced by CD4+ T lymphocytes remains subject to con-
troversy in mice [42]. Because of the structural similar-
ities between endogenous opioid neuropeptides, and
thereby the poor reliability of anti-opioid immune
sera, we used a genetic approach to show the pivotal
role of enkephalins in the analgesic property of CD4
+ T lymphocytes. We show, in CFA-induced pain
model in mice, that CD4+ T lymphocytes lacking en-
kephalins completely lose their analgesic activity.
Furthermore, the mechanical sensitivity of mice with
Fig. 5 Anti-β-endorphin polyclonal IgG antibodies do not bind to activated lymphocytes from pre-proenkephalin knockout mice as assessed
by cytofluorometry. CD4+ T lymphocytes isolated from wild-type C57Bl/6 (PENK+/+) mice (left panels) or pre-proenkephalin knockout (PENK−/−)
mice (right panels) were stimulated with both anti-CD3 and anti-CD28 mAbs for 6 days and intracellularly stained with either control rabbit
non-immune serum IgG (upper panels), rabbit anti-β-endorphin polyclonal IgG antibodies (middle panels), or rabbit anti-Met-enkephalin polyclonal
IgG antibodies (lower panels). The figure shows one representative experiment out of three performed
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enkephalin-deficient lymphocytes was superimposable
to that of mice without lymphocytes indicating that
the absence of enkephalins in T lymphocytes was
not compensated by another opioid.
Conclusions
Endogenous regulation of CFA-induced inflammatory
pain by CD4+ T lymphocytes is primarily mediated by
enkephalins in mice suggesting that β-endorphin would
be more relevant in rats and humans.
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